Finnrick Testing UK Reveals Key Peptide Purity & Potency Data for Brand Comparison
Published: July 11, 2026 19:00
Author: George Walker
Abstract: Finnrick Testing UK’s latest analysis provides critical peptide purity and potency data for brand comparison, revealing significant disparities in product composition and manufacturing standards. The study highlights that premium brands achieve >99% purity via HPLC/MS verification, while lower-tier products show degradation risks. Current market trends emphasize GMP-certified facilities and cold-chain logistics for stability. Key selection criteria include third-party COA validation, peptide type specificity (e.g., BPC-157 vs. TB-500), and lyophilized storage protocols. The data underscores the industry’s shift toward transparent sourcing and regulatory compliance, guiding informed brand choices.